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Abstract
Background: Hydrogen sulfide (H2S) displays vasodilative, anti-oxidative, anti-inflammatory and cytoprotective activities.
Impaired production of H2S contributes to the increased intrahepatic resistance in cirrhotic livers. The study aimed to
investigate the roles of H2S in carbon tetrachloride (CCl4)-induced hepatotoxicity, cirrhosis and portal hypertension.
Methods and Findings: Sodium hydrosulfide (NaHS), a donor of H2S, and DL-propargylglycine (PAG), an irreversible
inhibitor of cystathionine c-lyase (CSE), were applied to the rats to investigate the effects of H2S on CCl4-induced acute
hepatotoxicity, cirrhosis and portal hypertension by measuring serum levels of H2S, hepatic H2S producing activity and CSE
expression, liver function, activity of cytochrome P450 (CYP) 2E1, oxidative and inflammatory parameters, liver fibrosis and
portal pressure. CCl4 significantly reduced serum levels of H2S, hepatic H2S production and CSE expression. NaHS attenuated
CCl4-induced acute hepatotoxicity by supplementing exogenous H2S, which displayed anti-oxidative activities and inhibited
the CYP2E1 activity. NaHS protected liver function, attenuated liver fibrosis, inhibited inflammation, and reduced the portal
pressure, evidenced by the alterations of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST),
hyaluronic acid (HA), albumin, tumor necrosis factor (TNF)-a, interleukin (IL)-1b, IL-6 and soluble intercellular adhesion
molecule (ICAM)-1, liver histology, hepatic hydroxyproline content and a-smooth muscle actin (SMA) expression. PAG
showed opposing effects to NaHS on most of the above parameters.
Conclusions: Exogenous H2S attenuates CCl4-induced hepatotoxicity, liver cirrhosis and portal hypertension by its multiple
functions including anti-oxidation, anti-inflammation, cytoprotection and anti-fibrosis, indicating that targeting H2S may
present a promising approach, particularly for its prophylactic effects, against liver cirrhosis and portal hypertension.
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Introduction
Hydrogen sulfide (H2S) has displayed many physiological and
pathological activities [1]. Administration of H2S limited myocar-
dial infarct size caused by ischemia reperfusion injury (IRI) [2,3],
suppressed development of gastric ulcer [4], alleviated hypoxic
pulmonary hypertension [5], attenuated neuronal injury [6], and
prevented the development of hypertension [7]. An H2S-releasing
molecule, GYY4137, protected endotoxic shock by decreasing the
production of proinflammatory cytokines including tumor necrosis
factor-a (TNF-a) and interleukin-6 (IL-6) [8]. The multiple actions
of H2S mainly involve inhibiting oxidative stress [9], production of
lipid peroxidation and inflammatory factors [4], and activating
ATP sensitive potassium (KATP) channels [10].
H2S has also shown regulatory effects on hepatic physiology and
pathology [11]. H2S is endogenously produced in mammalian
tissues by cystathionine c-lyase (CSE) and cystathionine b-synthase
(CBS) [1], but CBS accounts for only 3% of H2S production in
livers [12]. CSE-derived H2S contributes to hepatic arterial buffer
response, mediates vasorelaxation of the hepatic artery via
activation of KATP channels [13], and modulates biliary
bicarbonate excretion [14]. H2S has exhibited anti-inflammatory
and cytoprotective activities against hepatic IRI [15], and
protected acetaminophen-induced hepatotoxicity in mice [16].
Diallyl trisulfide, an H2S-releasing chemical, protected from
carbon tetrachloride (CCl4)-induced liver injury [17,18].
The reduction of H2S production and CSE expression is related
to the development of increased intrahepatic resistance and portal
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and H2S counteracts the impaired vasodilation and hepatic stellate
cell contraction, which contribute to the dynamic component of
portal hypertension [20]. These two studies have focused on the
regulatory effects of H2S in already established portal hypertension
mainly by its vasodilative activities via activating KATP channels. As
mentioned in one report [20], liver fibrosis represents the main
causative factor in portal hypertension in cirrhosis, but the role of
H2S in the development of cirrhosis remains unclear. CCl4 has been
widely used to induce liver injury and cirrhosis in animal models, as
it is rapidly metabolized into the trichloromethyl radical by
cytochrome P450 (CYP) 2E1, and the reactive intermediate attacks
membrane lipids, resulting in the formation of lipid peroxide
molecules and necrosis of hepatocytes [21]. Given that H2S displays
anti-oxidative, anti-inflammatory and cytoprotective activities, an
anti-fibrotic effect against pulmonary fibrosis [22], and a regulatory
effect on hypoxic pulmonary hypertension [23] and portal
hypertension [19,20], we hypothesized that H2S might have a
protective effect against CCl4-induced acute hepatotoxicity, and the
resulting liver cirrhosis and portal hypertension.
Methods
Ethics Statement
All the procedures and care administered to the animals have
been approved by the institutional ethic committee, under a
permit of animal use (SYXK20020009) in the First Affiliated
Hospital of Harbin Medical University, compliance with the
Experimental Animal Regulations by the National Science and
Technology Commission, China.
Animals
Male Wistar rats (weighing 210-230 g) were supplied by the
Animal Research Center at the First Affiliated Hospital of Harbin
Medical University, Harbin, China. They were housed in the
animal facility with a 12-h-light/-dark cycle and the temperature
was maintained at 22-23uC.
Acute hepatotoxicity experiment
The rats received phenobarbital sodium (0.35 g/L) in drinking
water for 3 days, followed by a single i.p. injection of CCl4
(Nanjing Chem. Ltd., Nanjing, China) diluted in equal volume of
paraffin oil at a dose of 3 ml/kg body weight. Then the rats were
randomly assigned to 3 groups (each group had 6 rats): control,
NaHS and PAG, receiving an i.p. injection of 1 ml of physiological
saline, NaHS (Sigma-Aldrich) solution (14 mmol/kg body weight),
or PAG (Sigma-Aldrich) solution (50 mg/kg body weight),
respectively. The injection was repeated every 6 h. The rats were
killed 48 h after CCl4 administration. Six untreated rats served as
healthy controls. Blood was collected via cardiac puncture, and
serum was prepared by centrifugation at 20006g for 10 min, and
stored at -80uC. Livers were divided into two parts, one fixed in
10% buffered formalin, the other stored at -80uC.
Induction of liver cirrhosis
Liver cirrhosis was induced by CCl4 as described previously
[20,21]. Briefly, rats received phenobarbital sodium (0.35 g/L) in
drinking water for 3 days, followed by i.p. injections of 1 ml/kg
body weight of CCl4 diluted in an equal volume of paraffin oil
twice a week for 12 weeks.
Prevention experiment
Thirty-six rats receiving i.p. injections of CCl4 as above were
randomly assigned into 3 groups (each had 12 rats): saline, NaHS
and PAG, receiving i.p. injections of 1 ml of saline, NaHS solution
(10 mmol/kg body weight) and PAG solution (30 mg/kg body
weight), respectively, every two days for 12 weeks, starting on the
same day of CCl4 administration. 300 ml of blood samples were
collected by tail tipping at indicated time points. At completion of
the experiments, the rats were weighed, and the portal pressure
measured as below, and 300 ml of blood sample was collected from
the portal vein. The spleen was weighed as % of bodyweight and
used as a parameter for portal hypertension. Blood was collected
via cardiac puncture, and then the liver and spleen were collected.
Serum and liver samples were prepared and stored as above.
Measurement of portal pressure
The methodology has been described previously [24]. Briefly,
under anesthesia by an i.p. injection of sodium pentobarbital
(50 mg/kg body weight), rats underwent laparotomy, and a PE-
tube (23G, 0.6630 mm) was inserted over the ileocolic vein and
advanced toward the confluence of the portal and splenic veins.
This cannula was used to monitor portal pressure for 5 min by a
Medlab-Ug4Cs bio-signal processing system (Nanjing Medease
Science and Technology co., Ltd, Nanjing, China).
Treatment experiment
Rats with liver cirrhosis induced by 12-week administration of
CCl4 as above were randomly assigned to 3 groups (each had 6 rats):
saline, NaHS and PAG, receiving daily injection of 1 ml of saline,
NaHS solution (10 mmol/kg) and PAG solution (30 mg/kg),
respectively, for 5 days. At completion of the experiments, the portal
pressure measured, and then serum and liver samples were prepared.
Measuring H2S production in livers and H2S
concentration in sera
The methods have been described previously [15,25]. All
samples were assayed in triplicate and H2S was calculated against
a calibration curve of NaHS (0.122–250 mmol/L). The H2S
producing activity was expressed as mmole of H2S formed/g
tissues.
RT-PCR analysis
The analysis of CES mRNA by RT-PCR has been described
previously [15]. A pair of primers 59- GAC CTC AAT AGT CGG
CTT CGT TTC -39 and 59- CAG TTC TGC GTA TGC TCC
GTA ATG -39 to generate a 618 bp product of CSE mRNA. A
497 bp PCR product was amplified from glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) cDNA as an internal control,
with a pair of primers: 59-GAAGGTGAAGGTCGGAGT-39 and
39-TGAAACCATAGCACCTTCC-59. PCR products underwent
a 2% agarose gel electrophoresis, and the density of each band was
evaluated using the gel image analyzer (UV ChemiDOC, USA).
The relative density of mRNA levels was calculated as the
following formula: band density/ GAPDH band density.
Measurement of serum parameters
The serum levels of alanine aminotransferase (ALT), aspartate
aminotransferase (AST), hyaluronic acid (HA) and albumin were
measured with an auto-biochemical analyzer (Toshiba, Japan).
The serum levels of TNF-a, IL-6, interleukin-1b (IL-1b) and
soluble intercellular adhesion molecule-1 (ICAM-1) were mea-
sured with ELISA kits (BPB Biomedicals, Inc., USA).
Measurement of CYP2E1 activity in livers
The CYP2E1 activity was assayed using p-nitrophenol (Sigma-
Aldrich) as a substrate as described previously [26].
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glutathione (GSH)
Liver tissue was homogenized in a buffer containing 9 volumes
of 0.15 mol/L KCl-1.0 mmol/L EDTA to obtain 1:10 (w/v)
homogenates. Homogenates were then centrifuged at 10,000 g
(4uC) for 30 min to collect the supernatant for determining the
concentrations of MDA, GSH and total protein. MDA was
evaluated by the thiobarbituric acid reactive substances (TBARS)
method [27]. The final concentration of MDA was expressed as
mmol/g protein. GSH were measured using commercially
available kits (Jiancheng Institute of Biotechnology, Nanjing,
China) and expressed as nmol/mg protein. Protein concentration
of liver homogenate was determined by the Bradford method,
using bovine serum albumin as a standard [28].
Measurement of hepatic hydroxyproline
Hepatic hydroxyproline was measured as described previously
[29].
Histological analysis
Formalin-fixed liver specimens were embedded in paraffin,
sectioned, stained with hematoxylin and eosin (HE) or Masson,
and examined under light microscopy. Quantifying liver fibrosis
was performed by measuring blue pixels of the images taken from
Masson-stained sections. Ten photographs (200 6magnification)
were randomly taken from each liver at fixed exposure time and
conditions. The pictures were saved as JPEG (Joint photographic
experts group). The histogram function in Adobe Photoshop CS4
was used to count the blue pixels, and the numbers of red pixels
were recorded for each picture.
Western Blot analysis
The methodology has been described previously [15]. The Abs
against CSE or a-smooth muscle actin (a-SMA) (Santa Cruz
Biotechnology, Inc. Santa Cruz, CA) were used. The levels of
proteins were normalized with respect to band density of b-actin,
as an internal control.
Statistics
Results were expressed as mean values 6 standard deviation
(SD). A one-way analysis of variance (ANOVA) followed by the
post-hoc Dunnett’s test was used for evaluating statistical
significance (SPSS 17.0). A value of P,0.05 was considered
significant.
Results
H2S protects livers from CCl4-induced acute toxicity
Administration of NaHS significantly attenuated, while PAG
further raised, the elevated serum levels of ALT and AST by CCl4
(Table 1). The impaired liver function by CCl4 and the protective
effects of H2S were supported by the histological alterations
(Figure S1). The liver sections from healthy control rats showed
normal histology (Figure S1A). CCl4-treated livers had focal
midzonal necrosis and ballooning degeneration (Figure S1B).
NaHS attenuated the necrosis and vacuolization (Figure S1C),
while PAG further aggravated the hepatotoxicity and caused more
inflammatory cells infiltration (Figure S1D). NaHS also signifi-
cantly reduced the activity of CYP2E1, the major enzyme to
metabolize CCl4, in livers from CCl4-treated rats, compared with
saline, while either CCl4 or PAG had no effects on its activity
(Table 1). CCl4-treated rats had a significant higher level of
hepatic MDA (a marker of lipid peroxidation) and a significantly
lower level of hepatic GSH, compared to healthy controls. NaHS
significantly attenuated the increase of hepatic MDA, and restored
hepatic GSH, but PAG only had slight effects on hepatic MDA
and GSH, in CCl4-treated rats, compared with saline (Table 1).
Serum levels of H2S, production of H2S and CSE
expression in the acute experiment
The serum levels of H2S in CCl4 + saline-treated rats were
significantly lower than that in healthy controls (P,0.05) (Fig. 1A),
supported by that CCl4 significantly (P ,0.05) reduced hepatic
H2S producing activity (Fig. 1B). Hepatic expressions of CSE
mRNA (Fig. 1C and D) and protein (Fig. 1E and F) were
significantly (Both P,0.05) lower in CCl4-treated rats than that in
healthy controls. NaHS significantly (P,0.001) increased the levels
of H2S (Fig. 1A), but had no effect on hepatic H2S producing
activity (Fig. 1B) and the expression of CSE mRNA (Fig. 1C and
D) and protein (Fig. 1E and F), in CCl4-treated rats, compared
saline. However, PAG significantly (Both P,0.05) reduced the
levels of H2S (Fig. 1A) and H2S producing activity (Fig. 1B), but
had no effect on the expression of CSE mRNA (Fig. 1C and D)
and protein (Fig. 1E and F), in CCl4-treated rats, compared with
saline.
H2S production in cirrhotic rats induced by CCl4
Among the rats in the prevention experiment, one from the
CCl4 + saline group and two from the CCl4 + PAG group died
Table 1. Serum ALT and AST, and hepatic CYP2E1, MDA and GSH in hepatotoxicity experiment*.
Healthy control CCl4
saline NaHS PAG
(n=6) (n=6) (n=6) (n=6)
Serum ALT (IU/L) 36.267.5 245.8636.5
a 149.6625.7
a,b 268.7646.9
a,b
Serum AST (IU/L) 78.9611.4 657.0696.1
a 427.66102.3
a,b 835.26133.5
a,b
Liver CYP2E1(mmol/g protein) 2.860.2 2.760.4 1.460.3
a,b 3.161.0
Liver MDA (mmol/g protein) 1.660.3 5.961.2
a 3.860.7
a,b 6.361.5
a
Liver GSH (mmol/g protein) 11.562.4 5.761.8
a 10.763.0
a,b 4.661.1
a
*The blood and liver samples were collected from the rats 48 h after CCl4 administration. Data are expressed as means 6 SD, and statistical analysis was performed by
one-way ANOVA analysis followed by the post-hoc Dunnett’s test.
aSignificant difference (P,0.05) from healthy controls.
bSignificant difference (P,0.05) from saline -treated rats.
doi:10.1371/journal.pone.0025943.t001
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study. Blood samples were collected at indicated time points to
measure the serum levels of H2S in rats. The healthy rats had a
stable serum level of H2S, while the H2S levels in CCl4-induced
cirrhotic rats receiving injection of saline declined at week 4 after
CCl4 administration, and continued dropping as the H2S levels
were even lower at week 8 and 12 than that at week 4 (Fig. 2A).
However, NaHS significantly (P,0.05) elevated the serum level of
H2S at week 4 after CCl4 administration in CCl4-induced cirrhotic
rats, compared with saline, and serum H2S was maintained at a
higher level at week 8 and 12 (Fig. 2A). Administration of PAG
resulted in significantly (All P,0.05) lower serum levels of H2Si n
Figure 1. Serum levels of H2S, H2S production and CSE expression in CCl4-induced acute hepatotoxicity. Healthy rats, or CCl4-treated
rats receiving administrations of saline, NaHS or PAG, were killed 48 h after CCl4 administration, blood and liver samples were collected. The levels of
H2S in sera (A) and H2S producing activity in livers (B) were measured. (C-F) The expression of CSE mRNA (C, D) and protein (E, F) was detected in liver
tissues from healthy rats (lane 1), or CCl4-treaed rats receiving administration of saline (lane 2), NaHS (lane 3) or PAG (lane 4), by RT-PCR (C, D) or
Western blot analysis (E, F), respectively. M, DNA marker. (D) The density of each band from (C) was measured and compared to that of the internal
control, GAPDH. (F) The density of each band from (E) was measured and compared to that of the internal control, b-actin. Results are expressed as
mean 6 SD (n=6). Compared to the healthy controls, a significant difference is denoted by ‘‘*’’ , and a highly significant difference by ‘‘**’’ (P,0.001).
Compared to rats treated with CCl4 + saline, a significant increase is denoted by ‘‘{’’, and a significant reduction is denoted by ‘‘#’’.
doi:10.1371/journal.pone.0025943.g001
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(Fig. 2A). The portal serum levels of H2S at the completion of
experiment was significantly (P,0.05) lower in CCl4-induced
cirrhotic rats receiving injection of saline than the healthy controls
(Fig. 2B). However, NaHS significantly (P,0.05) elevated, but
PAG did not significantly (P.0.05) decrease, the portal serum
levels of H2S, in CCl4-induced cirrhotic rats, compared with saline
(Fig. 2B). We further examined the H2S producing activity (Fig. 2
C) in livers from CCl4-induced cirrhotic rat receiving injections of
saline, NaHS or PAG, and the similar results were obtained as
Figure 2. Serum H2S levels, H2S production, and expression of CSE and a-SMA in the prevention experiment. The rats were treated
with CCl4 + saline, CCl4 + NaHS or CCl4 + PAG for 12 weeks. Untreated rats served as healthy controls. (A) Blood samples were collected at indicated
time points, and the serum levels of H2S were measured. The statistical comparison between two groups was done at the respective time point. (B-E)
The rats were killed at the completion of experiment. Blood samples were collected from portal vein, and livers harvested. The levels of H2S in sera
from the portal vein (B), and H2S producing activity in livers (C) were measured. (D) The expression of CSE and a-SMA was detected in livers from
healthy controls (lane 1), or rats treated saline+CCl4 (lane 2), NaHS+CCl4 (lane 3) or PAG+CCl4 (lane 4) by Western blot analysis. (E) The density of each
band was measured and compared to that of the internal control, b-actin. Results are expressed as mean 6 SD. n, number of samples. Compared to
the healthy controls, a significant difference is denoted by ‘‘*’’, a highly significant difference by ‘‘**’’ (P,0.001). Compared to saline + CCl4-treated
rats, a significant increase is denoted by ‘‘{’’, and a significant reduction is denoted by ‘‘#’’.
doi:10.1371/journal.pone.0025943.g002
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by the results of hepatic CES expression (Fig. 2D and E), where
CCl4 significantly downregulated, while NaHS or PAG had no
effect on, the expression of CES.
H2S attenuates the impaired liver function and elevated
inflammatory factors in cirrhotic rats
Cirrhotic rats induced by 12-week administration of CCl4 had
significantly higher levels of ALT, AST, HA and lower level of
albumin, than healthy controls (Table 2). However, simultaneous
administration of NaHS resulted in significantly lower levels of
ALT, AST and HA, and higher level of albumin, while PAG led to
significantly higher levels of AST and HA, slight increase of ALT
level and slight reduction of albumin level, in CCl4-induced
cirrhotic rats, compared with saline (Table 2).
Cirrhotic rats had significantly higher levels of proinflammatory
cytokines including TNF-a, IL-1b and IL-6, and soluble ICAM-1
(Table 2), which have been shown to play important roles in
development of cirrhosis. However, simultaneous administration
of NaHS resulted in significantly lower levels of all the four
parameters in CCl4-induced cirrhotic rats than saline, while PAG
led to significantly higher levels of TNF-a and soluble ICAM, and
slight increase of IL-1b and IL-6, in CCl4-induced cirrhotic rats,
compared with saline (Table 2).
H2S attenuates CCl4-induced liver cirrhosis and portal
hypertension
The Masson-stained liver sections from healthy controls had
almost no collagen fibers of blue color (Fig. 3A), but those from
CCl4-induced cirrhotic rats injected with saline had abundant and
widespread fibers of blue color (Fig. 3B). However, the liver
sections from CCl4-induced cirrhotic rats injected with NaHS had
fewer fibers (Fig. 3C), while those from PAG-injected cirrhotic rats
(Fig. 3D) had even more fibers, compared with those from saline-
injected cirrhotic rats. The numbers of blue pixels in Masson-
stained liver sections were measured to quantify collagen fibers.
CCl4 highly significantly (P,0.001) increased the number of blue
pixels in liver sections (Fig. 3E). However, administration of NaHS
resulted in a significant (P,0.05) lower number of blue pixels, but
PAG, a significant (P,0.05) higher number of blue pixels, in CCl4-
induced cirrhotic rats, compared with saline (Fig. 3E). We further
measured hydroxyproline, a marker of fibrosis, and found that
CCl4-treated rats had significantly (P,0.001) higher hepatic
hydroxyproline content than the healthy controls. However,
administration of NaHS significantly (P,0.05) reduced, but
PAG did not significantly (P.0.05) increase, the hepatic
hydroxyproline contents in CCl4-induced cirrhotic rats, compared
with saline (Fig. 3F). Next, we detected hepatic expression of a-
SMA, another marker of liver fibrosis, and found that the CCl4-
treated rats had significantly higher hepatic expression of a-SMA,
compared to the healthy controls. However, administration of
NaHS significantly (P,0.05) downregulated, but PAG did not
significantly (P.0.05) increase, hepatic expression of a-SMA in
CCl4-induced cirrhotic rats, compared with saline (Fig. 2D and E).
The spleen weight and portal pressure were used as parameters
for portal hypertension. The spleen weight of CCl4–treated rats
was highly significantly (P,0.001) higher than that of healthy
controls (Fig. 3G). However, administration of neither NaHS nor
PAG resulted in significant difference in spleen weight of CCl4-
induced cirrhotic rats, compared with saline (Fig. 3G). CCl4-
induced cirrhotic rats had a significantly (P,0.001) higher portal
pressure than the healthy controls (Fig. 3H). However, adminis-
tration of NaHS resulted in a significant (P,0.05) lower level of
portal pressure, while PAG, a significant (P,0.05) higher level of
portal pressure, in CCl4-induced cirrhotic rats, than saline
(Fig. 3H).
The therapeutic effect of H2S on liver cirrhosis and portal
hypertension
Given that H2S displayed a preventive effect against CCl4-
induced liver cirrhosis and portal hypertension, we next
investigated whether H2S could have a similar therapeutic effect
in already established liver cirrhosis. Liver cirrhosis was induced in
rats by 12-week administration of CCl4 as above, and then saline,
NaHS or PAG was administered to the cirrhotic rats, respectively,
for 5 days. Administration of NaHS significantly (Both P,0.05)
elevated the levels of H2S in sera from the peripheral blood
(Fig. 4A) and portal vein (Fig. 4B), but again had no effect on H2S
production activity in livers (Fig. 4C). PAG significantly (P ,0.05)
reduced the levels of H2S in sera from the systemic circulation
(Fig. 4A), marginally significantly (P=0.07) reduced the levels of
H2S in the portal vein (Fig. 4B), and significantly (P ,0.05)
reduced the H2S production in livers (Fig. 4C). NaHS or PAG had
no significantly influence on the histological alterations of livers
(Data not shown), and the hepatic hydroxyproline in NaHS or
PAG-treated rats were not significant different from the saline-
Table 2. Serum biochemicals and inflammatory factors in cirrhotic rats*.
Healthy control CCl4 + saline CCl4 + NaHS CCl4 + PAG
(n=6) (n=11) (n=12) (n=10)
ALT (IU/L) 34.468.9 198.8626.7
a 137.6620.3
a,b 208.5636.4
a
AST(IU/L) 80.3612.5 466.7646.4
a 317.5678.2
a,b 515.0697.6
a,b
HA (mg/L) 113.5620.1 482.6651.4
a 296.3632.1
a,b 549.0647.3
a,b
Albumin (g/L) 472.5643.8 314651.6
a 443.7680.5
a,b 294.3632.8
a
TNF-a (ng/L) 43.966.8 143.5621.4
a 109.3622.6
a,b 176.3628.5
a,b
IL-1b(ng/L) 20.365.0 75.4610.2
a 50.669.8
a,b 80.2617.4
a
IL-6 (ng/L) 87.0615.9 297.1655.4
a 216.4642.1
a,b 320.6651.4
a
ICAM-1(ng/L) 69.268.7 180.8619.7
a 153.6622.8
a,b 207.2631.3
a,b
*Data are expressed as means 6 SD, and statistical analysis was performed by one-way ANOVA analysis followed by the post-hoc Dunnett’s test.
aSignificant difference (P,0.05) from healthy controls.
bSignificant difference (P,0.05) from CCl4+saline-treated rats.
doi:10.1371/journal.pone.0025943.t002
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Representative illustrations (200 6magnification) of Masson-stained liver sections were taken from healthy controls (A), or rats treated with CCl4 +
saline (B), CCl4 + NaHS (C) or CCl4 + PAG (D), for 12 weeks. (E) The numbers of blue pixels of each image of the above Masson-stained liver sections
were counted, and the average number of blue pixels for each liver was calculated. (F) The level of hydroxyproline in livers taken from the above rats
was measured. (G) Each spleen was weighed as % of bodyweight. (H) The portal pressure of each was measured. Data were expressed mean 6 SD. n,
number of samples. Compared to the healthy controls, a significant difference is denoted by ‘‘*’’, and a highly significant difference, by ‘‘**’’
(P,0.001). Compared to saline + CCl4-treated rats, a significant increase is denoted by ‘‘{’’, and a significant reduction is denoted by ‘‘#’’.
doi:10.1371/journal.pone.0025943.g003
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significantly (P,0.05) reduced the portal pressure, while PAG
significantly (P,0.05) elevated the portal pressure, compared with
saline (Fig. 4E), but their effects on spleen weight were not
significant, compared with saline (Fig. 4F).
Discussion
CCl4 has been widely used as a chemical model to induce
hepatotoxicity, liver cirrhosis and portal hypertension, since it is
metabolized into trichloromethyl radical, leading to increased lipid
peroxidation, depletion of GSH, impaired hepatic anti-oxidant
activity and necrosis of hepatocytes [21,30]. The present study has
demonstrated that CCl4 downregulated the expression of CSE, the
major enzyme accounting for 97% of H2S production in livers
[1,12,19], resulting in decreased hepatic H2S producing activity.
Administration of NaHS, a donor of H2S, attenuated CCl4-induced
acute hepatotoxicity, evidenced by the reduction of serum levels of
AST and ALT, and attenuation of histopathological alterations, in
accordance with the previous reports on its cytoprotective effects
against myocardial IRI [2], endotoxin-induced cardiac injury [31],
hepatic IRI [15], acetaminophen-induced hepatotoxicity [16], or
gastric mucosa damage caused by stress [4], nonsteroidal anti-
inflammatory drugs [32] or oxidative stress [33]. The protective
effects of H2S may rely on its anti-oxidative activity by reducing the
production of lipid peroxides, as NaHS inhibited the activity of
CYP2E1, one of the major enzymes metabolizing CCl4 [21]. The
vasodilative activity of H2S may also contribute this protective
activity, as H2S-induced vasorelaxation [34] can improve micro-
circulation of livers, which help livers to get rid of excessive lipid
peroxides. In addition, though not investigated herein, the anti-
apoptotic activity of H2S as demonstrated against hepatic IRI [15],
may also contribute to this action.
The effects of CCl4 on H2S production were shown to be
accumulative as the serum levels of H2S declined in a time-
dependent course. NaHS had no effect on either hepatic CSE
expression or H2S producing activity, and led to a relatively higher
but stable level of H2S in sera, implying that the body has the
ability to adjust endogenous production of H2S or get rid of
excessive H2S, which has been recognized as a ‘‘toxic gas’’ in
environmental pollution [35]. In both the acute and prevention
experiments, PAG, an irreversible inhibitor of CSE, significantly
suppressed the H2S producing activity and reduced the H2S levels,
thus showing opposite effects to NaHS on liver function, lipid
peroxides, and liver fibrosis, but had no impact on CSE
expression, in accordance with previous reports [3,15].
The present study has for the first time demonstrated the anti-
fibrotic activity of H2S against liver cirrhosis, evidenced by
reduced number of collagenous fibers in livers, and hepatic
hydroxyproline content and expression of a-SMA. Besides the
direct mechanism on fibrogenesis, the protective effect of H2So n
hepatic injury also contributes to its anti-fibrotic activity. In
addition, NaHS inhibited the production of inflammatory factors
including TNF-a, IL-1b, IL-6, soluble ICAM-1. The anti-
inflammatory effect, particular inhibition of IL-6 production by
H2S, can contribute to its anti-fibrotic activity, as IL-6 is
Figure 4. H2S levels and production, hepatic hydroxyproline, portal pressure and spleen weight in the treatment experiment. Liver
cirrhosis was induced in rats as in Figure 3, and then the rats were assigned to three groups (Each group had 6 rats), and received daily injection of
saline, NaHS or PAG, respectively, for 5 days, and then killed. (A) Blood samples were collected and the serum levels of H2S were measured. (B) Blood
samples were collected from portal vein to measure the levels of H2S in portal vein (B). The hepatic H2S producing activity (C) and hydroxyproline
contents (D) were measured. The portal pressure was measured (E), and each spleen was weighed as % of bodyweight (F). Results are expressed as
mean 6 SD. A significant increase from saline-treated rats is denoted by ‘‘{’’, and a significant reduction by ‘‘#’’.
doi:10.1371/journal.pone.0025943.g004
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process in an autocrine/paracrine manner [36].
The regulation of sinusoidal resistance depends on the
contraction of hepatic stellate cells (HSCs) around sinusoidal
endothelial cells [19]. It has been demonstrated that H2Si sa n
autocrine mediator involved in regulating HSCs contraction and
maintaining portal venous pressure by targeting KATP channels
[19]. H2S can counteract the impaired vasodilation and HSC
contraction, thus reducing portal hypertension, cirrhotic livers
[20]. The results presented herein further support the effects of
H2S on portal hypertension as administration of NaHS showed
prophylactic and therapeutic effects in reducing portal hyperten-
sion. The protective effects of H2S on liver cirrhosis may also
attributes to this effect in the prevention experiment, as liver
fibrosis represents the main causative factor in portal hypertension
[20]. However, H2S did not show significant therapeutic effects on
liver cirrhosis in the treatment experiment, based on the
histological alterations and hepatic hydroxyproline contents in
cirrhotic rats, indicating H2S may not have the ability to reverse
the process of liver fibrosis.
In conclusion, the present study has for the first time
systemically investigated the potential protective role of H2So n
CCl4-induced acute hepatotoxicity, the prophylactic effect of H2S
on long-term CCl4-induced cirrhosis and portal hypertension, and
the therapeutic effect of H2S on portal hypertension, by its
multiple functions including anti-oxidation, anti-inflammation,
cytoprotection and anti-fibrosis. The results indicate that targeting
H2S may present a potent approach, particularly for its
prophylactic effects, against liver cirrhosis and portal hypertension.
Preclinical trials by applying some promising H2S-relesasing
chemicals have already been launched though at their infancy.
For instance, diallyl trisulfide, a stable H2S donor and organic
polysulfide compound [37], has been shown to protect from
carbon tetrachloride (CCl4)-induced liver injury [17,18]. However,
cautions must be taken as H2S has been recognized as a ‘‘toxic
gas’’ [35], and more preclinical trials are required before H2S-
releasing agents reach the clinics for use in preventing liver
cirrhosis and portal hypertension.
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